The treatment of metastatic clear-cell renal cell cancer (mccRCC) has seen substantial progress over the last decade. Until 2006, non-specific immunotherapy with high dose interleukin-2 (HD IL-2) was considered as standard therapy of mccRCC. The transition from cytokine to targeted therapy, and now to novel immunotherapeutic agents, significantly increased the overall survival (OS) of patients […]
No validated molecular biomarkers exist to help guide prognosis of renal cell carcinoma (RCC) patients. We seek to evaluate the quality of published prognostic circulating RCC biomarker manuscripts using the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines. The phrase “(renal cell carcinoma OR renal cancer OR kidney cancer OR kidney carcinoma) AND circulating […]
Active surveillance, now the standard of care for most men with favorable risk prostate cancer, is appealing for selected men with ‘favorable’ intermediate risk prostate cancer. This is a review of the indications for conservative management in this population, the outcome reported in prospective series, and the use of molecular biomarkers and imaging to identify […]
MRI-targeted prostate biopsy may be an attractive alternative to systematic biopsy for diagnosing clinically significant prostate cancer. In this narrative review, we discuss the new developments that have occurred in the advancement of MRI-targeted prostate biopsy, over the past 24 months. MRI-targeted biopsy offers enhanced diagnostic accuracy, when compared with the current standard of care […]
In this review, we present an update on the safety and efficacy of prostate-specific membrane antigen (PSMA) radioligand therapy (PRLT) of metastatic castration-resistant prostate cancer (mCRPC). Treatment of mCRPC with approved treatment agents leads to a survival advantage. The disease often progresses despite these treatments. PRLT with Lutetium-177 and Actinium-225 labeled with PSMA (LuPSMA and […]
We investigated the utility of multiparametric magnetic resonance imaging (mpMRI) using Prostate Imaging Reporting and Data System, version 2 (PI-RADSv2), scoring in patients with prostate cancer eligible for active surveillance (AS). The medical records of the patients who had undergone mpMRI before radical prostatectomy from 2014 to 2018 were reviewed. All the patients had met […]
Active surveillance (AS) is an accepted means of managing low-risk prostate cancer. Because of the rarity of downstream events, data from existing AS cohorts cannot yet address how differences in surveillance intensity affect metastasis and mortality. This study projected the comparative benefits of different AS schedules in men diagnosed with prostate cancer who had Gleason […]
Stress urinary incontinence (SUI) following radical prostatectomy (RP) is common and potentially debilitating. For men who fail conservative measures to treat post-prostatectomy incontinence (PPI), surgical therapy with either a urethral sling or artificial urinary sphincter (AUS) is an effective option with high patient satisfaction. We sought to characterize the contemporary utilization of surgical therapy for […]
Las Vegas, Nevada (UroToday.com) Mr. Gleason gave a talk on the licensing and regulatory requirements for targeted alpha therapies. He began with a brief history of the atomic energy commission (AEC)/Nuclear Regulatory Commission (NRC). The Atomic energy act of 1946 established the nuclear responsibility of the AEC. In 1954 the atomic energy act made commercial nuclear […]
Las Vegas, Nevada (UroToday.com) Concluding this meeting, Dr. Daniel Pryma gave a brief overview of the important topics that were covered in the meeting. These were described in 11 distinct points: Radionuclide therapies do not fit neatly into any existing treatment delivery workflows. There is a need to be thoughtful and creative in working out new […]
